|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||19.75 - 20.25|
|52 Week Range||10.23 - 25.35|
|Beta (3Y Monthly)||4.06|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.67|
Accelerate Diagnostics Inc NASDAQ:AXDXView full report here! Summary * Bearish sentiment is high Bearish sentimentShort interest | NegativeShort interest is extremely high for AXDX with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting AXDX. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold AXDX had net inflows of $1.13 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
TUCSON, Ariz., March 8, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX) announced today that the company is scheduled to present at the Cowen and Company 39th Annual Health Care Conference in Boston on Wednesday, March 13, 2019 at 8:40 AM Eastern Time. Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis.
Accelerate Diagnostics Inc (AXDX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Accelerate Diagnostics Inc is an in vitro diagnostics company, dedicated in providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Warning! GuruFocus has detected 4 Warning Signs with MMI.
Larry Mehren has been the CEO of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) since 2012. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. ThenRead More...
TUCSON, Ariz. (AP) _ Accelerate Diagnostics Inc. (AXDX) on Tuesday reported a loss of $22.2 million in its fourth quarter. The average estimate of three analysts surveyed by Zacks Investment Research was also for a loss of 41 cents per share. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.
TUCSON, Ariz. , Feb. 19, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced financial results for the fourth quarter and fiscal year ended December 31 , 2018. "I am ...
NEW YORK, NY / ACCESSWIRE / February 19, 2019 / Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 19, 2019 ...
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Feb. 08, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
TUCSON, Ariz. , Feb. 5, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Tuesday, February 19, 2019 at 4:30 p.m. Eastern Time to review 2018 ...
TUCSON, Ariz., Jan. 2, 2019 /PRNewswire/ -- Accelerate Diagnostics announced today that the company is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019, at 2:30 PM Pacific Time. About Accelerate Diagnostics, Inc. Accelerate Diagnostics, Inc. (AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
TUCSON, Ariz., Nov. 27, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. has joined with Sepsis Alliance to celebrate #GivingTuesday, November 27th, a global day of giving that harnesses the collective power of individuals, communities and organizations to encourage philanthropy and to celebrate generosity worldwide. Accelerate Diagnostics has pledged to match the first $15,000 donated to Sepsis Alliance on #GivingTuesday to help raise awareness of sepsis as an often preventable medical emergency and improve outcomes for patients affected by sepsis through expanded healthcare provider education. Any infection can lead to sepsis, which is now the third leading cause of death in the United States.
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.82% and -53.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?